Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A ...
Evaluating the impact of a clinical universal mismatch repair screening initiative. This is an ASCO Meeting Abstract from the 2012 Quality Care Symposium. This abstract does not include a full text ...
Early stage GIST may be curable, but there is a risk of recurrence. The overall relative 5-year survival rate for GIST is 83 percent, but this varies by stage and other factors. Newer therapies offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results